New Study Finds Hypertension Accelerates Bone Aging

A new study has found that high blood pressure (hypertension) may accelerate bone aging, as observed in mice models. The research was presented during this year’s Hypertension Scientific Sessions conference, hosted by the American Heart Association.

The researchers’ objective was to understand how high blood pressure contributed to osteoporosis and help find ways to decrease the risk of the bone disease and better protect individuals from experiencing fragility fractures later in life. For their study, the researchers examined inflammation linked to hypertension in mice. This led to the discovery that high blood pressure may be linked to osteoporosis.

Hypertension and osteoporosis are prevalent illnesses that have comorbidity, meaning that they can occur at the same time. Osteoporosis is a condition that weakens an individual’s bones, making the bones more fragile. Osteoporosis usually develops slowly over a period of time and is diagnosed when an injury causes a bone to fracture.

The lead author of the study, Elizabeth Maria Hennen, stated that the human age equivalent was between 20 to 30 years and 47 to 55 years for the young and old mice respectively.

To induce hypertension, the researchers administered angiotensin II to a group of young mice for six weeks. After the period had elapsed, they compared the young mice with induced high blood pressure to older mice without high blood pressure in order to evaluate the relationship between the disease and bone aging.

The researchers conducted an analysis of the bones of the mice using an advanced imaging method known as microcomputed tomography. They determined the health of the bones based on bone density and strength. They also used mathematical algorithms to estimate the effects of aging and high blood pressure on the strength and microstructure of the mice’s bones.

The researchers found that in comparison to the mice without hypertension, those with induced hypertension had an almost 35% reduction in estimated failure force, an almost 20% decrease in the thickness of the trabecular bone and about 25% decrease in bone volume fraction. The trabecular bone is located at the end of long bones such as femurs, while failure force is the bones’ ability to withstand different types of force.

In their report, Hennen stated that failure force translated into weaker bones, noting that bone weakness in the spine could lead to vertebral fractures as individuals grew older. In addition to this, the researchers observed that the older mice, both those with or without high blood pressure, displayed a reduced bone quality that was akin to that of the hypertensive young mice.

Significant strides are being made in the field of heart disease diagnostics and treatment. For example, Odyssey Health Inc. (OTC: ODYY) is in the advanced stages of developing a noninvasive device that will help in the accurate prediction and diagnosis of heart disease so that treatment can be started promptly. Such interventions can potentially avert complications such as bone aging that result when high blood pressure isn’t managed properly.

NOTE TO INVESTORS: The latest news and updates relating to Odyssey Health Inc. (OTC: ODYY) are available in the company’s newsroom at https://ibn.fm/ODYY

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.